• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

UCLA, PreciseDx to Develop AI-Powered Breast Cancer Recurrence Tool for Early Detection

by Fred Pennic 04/08/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
UCLA, PreciseDx to Develop AI-Powered Breast Cancer Recurrence Tool for Early Detection

What You Should Know: 

– PreciseDx®, a leader in AI-powered diagnostics for oncology, announces a crucial collaboration with UCLA’s Department of Pathology and Laboratory Medicine. 

– The research initiative focuses on evaluating PreciseDx’s innovative tool, PreciseBreast™, for its ability to accurately assess the risk of recurrence in patients diagnosed with triple-negative breast cancer (TNBC).

Why Focus on Triple-Negative Breast Cancer?

  • TNBC Challenges: Accounting for only 10-20% of breast cancer cases, TNBC is particularly aggressive and carries a higher risk of recurrence. It is often linked to younger women, BRCA1/2 gene mutations, and ethnic/racial disparities. Traditional treatments offer limited effectiveness.
  • Need for Advanced Tools: Recent discoveries of TNBC subtypes and the potential of immunotherapy highlight the urgent need for more sophisticated tools for TNBC categorization and risk assessment. This is crucial for developing personalized treatment plans and improving patient outcomes.

Building on Previous Success

This new study expands upon a prior subgroup analysis of TNBC patients from the PreciseBreast-Mount Sinai Hospital validation study. UCLA’s involvement allows for the evaluation of a larger, well-annotated TNBC cohort from the UCLA Health System.

The Power of AI and Collaboration

The collaborative study integrates cutting-edge AI algorithms with comprehensive clinical data. The goal is to validate PreciseBreast™ as a reliable digital breast cancer assay for:

  • Enhanced Early Detection: PreciseBreast™ aims to identify TNBC recurrence at an earlier stage, allowing for timely intervention.
  • Personalized Treatment Strategies: This AI-powered tool can potentially support the development of individualized treatment plans based on each patient’s specific needs.
  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Breast Cancer

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Digital Health Funding Q3 2025: Choppy Undercurrents Beneath a Steady Surface

Featured Interview

ConcertAI VP Shares View on AI Hallucinations and the Fabricated Data Crisis in Scientific Publishing

Most-Read

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Oracle Confirms Layoffs in Kansas City

Oracle Confirms Layoffs in Kansas City

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Optain Health Secures $26M to Advance AI-Powered Retinal Screening

Optain Health Secures $26M for AI-Powered Retinal Screening

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |